A BILL 
To require the Secretary of Health and Human Services 
to conduct a demonstration program to genetic and 
genomic testing for certain children, to provide for a 
study by the National Academy of Medicine on the use 
of such testing to improve health care, and for other 
purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
06:43 Nov 17, 2021
H5989
2 
•HR 5989 IH
SECTION 1. SHORT TITLE. 
1
This Act may be cited as the ‘‘Precision Medicine An-
2
swers for Kids Today Act’’. 
3
SEC. 2. CENTERS FOR MEDICARE & MEDICAID SERVICES 
4
GUIDANCE ON THE EARLY AND PERIODIC 
5
SCREENING, DIAGNOSTIC, AND TREATMENT 
6
BENEFIT. 
7
Not later than 6 months after the date of enactment 
8
of this Act, the Centers for Medicare & Medicaid Services 
9
shall issue guidance to States on authority and require-
10
ments under the Medicaid program under title XIX of the 
11
Social Security Act to provide medically necessary health 
12
care that falls within the scope of services specified under 
13
section 1905(r) of the Social Security Act (42 U.S.C. 
14
1396d(r)) to a child, regardless of whether the service is 
15
available for adults under the State plan (or waiver of 
16
such plan) under such title. The guidance shall— 
17
(1) include technical and educational assistance 
18
on how to increase the frequency of coverage under 
19
the State plan (or waiver) pursuant to paragraphs 
20
(4) and (16) of section 1905(a) of such Act (42 
21
U.S.C. 1396d(a)) for genetic and genomic testing di-
22
agnostic services, including whole exome sequencing, 
23
whole genome sequencing, and gene panels when rec-
24
ommended by a qualified treating provider as a first- 
25
06:43 Nov 17, 2021
H5989
3 
•HR 5989 IH
or second-tier test for pediatric patients, including 
1
those who— 
2
(A) have a positive result from a newborn 
3
screening program; 
4
(B) have one or more neurodevelopmental 
5
or congenital anomalies; 
6
(C) are experiencing developmental delay 
7
or intellectual disability; 
8
(D) are having seizures; 
9
(E) have been referred or admitted to a 
10
pediatric or neonatal intensive care unit for a 
11
chronic or undiagnosed disease; 
12
(F) have been seen by at least one medical 
13
specialist for such chronic or undiagnosed dis-
14
ease; or 
15
(G) are suspected by at least one 
16
healthcare provider to have a neonatal- or pedi-
17
atric-onset genetic disease; 
18
(2) provide education and support to providers 
19
to minimize denials of claims for medical assistance 
20
under the State plan under title XIX of the Social 
21
Security Act resulting from deficient or inadequate 
22
paperwork; and 
23
(3) ensure that providers and Medicaid-eligible 
24
children and the families are aware of the Early and 
25
06:43 Nov 17, 2021
H5989
4 
•HR 5989 IH
Periodic Screening, Diagnostic and Treatment Ben-
1
efit under title XIX of the Social Security Act and 
2
have access to required screenings and necessary 
3
treatment services. 
4
SEC. 3. DEMONSTRATION PROGRAM TO PROVIDE GENETIC 
5
AND GENOMIC TESTING FOR CERTAIN CHIL-
6
DREN. 
7
(a) IN GENERAL.—The Secretary of Health and 
8
Human Services shall enter into agreements with up to 
9
15 States submitting applications under subsection (c) for 
10
the purpose of conducting, in accordance with this section, 
11
3-year demonstration projects under section 1115 of the 
12
Social Security Act (42 U.S.C. 1315) in such States dur-
13
ing the 3-year period beginning on the first date of the 
14
first fiscal quarter than begins on or after the date of the 
15
enactment of this section to test and evaluate the provision 
16
of medical assistance under the State plans under title 
17
XIX of such Act (or waivers of such plans) to eligible indi-
18
viduals for purposes of providing such individuals with ge-
19
netic and genomic testing. 
20
(b) DEMONSTRATION PROJECT PAYMENT REQUIRE-
21
MENTS.—Under each demonstration project under this 
22
section conducted by a State, the following shall apply: 
23
(1) The State shall provide a health care pro-
24
vider (as defined by the State) with payments for 
25
06:43 Nov 17, 2021
H5989
5 
•HR 5989 IH
the provision of genetic and genomic testing to any 
1
eligible individual. Payments made to a health care 
2
provider for such services shall be treated as medical 
3
assistance for purposes of section 1903(a) of the So-
4
cial Security Act (42 U.S.C. 1396b(a)), except that 
5
the Federal medical assistance percentage applicable 
6
to such payments shall be equal to 100 percent. 
7
(2) The State shall specify the methodology the 
8
State will use for determining payment for the provi-
9
sion of genetic and genomic testing. Such method-
10
ology for determining payment shall be established 
11
consistent with section 1902(a)(30)(A) of such Act 
12
(42 U.S.C. 1396a(a)(30)(A)). 
13
(c) APPLICATIONS.— 
14
(1) IN GENERAL.—A State desiring to enter 
15
into an agreement under subsection (a) with the 
16
Secretary for conducting a demonstration project 
17
shall submit to the Secretary an application, in ac-
18
cordance with such form and manner, and applica-
19
tion priorities, as specified by the Secretary and that 
20
at a minimum includes the following: 
21
(A) An explanation of how and the extent 
22
to which genetic and genomic testing under the 
23
demonstration project of the State will provide 
24
06:43 Nov 17, 2021
H5989
6 
•HR 5989 IH
information and data on how such services im-
1
prove the diagnosis of eligible individuals. 
2
(B) An explanation of how and the extent 
3
to which coverage under the State plan (or 
4
waiver) pursuant to the demonstration project 
5
will increase the use of genetic and genomic 
6
testing that may increase the use of genetic and 
7
genomic testing that may improve clinical out-
8
comes for eligible individuals. 
9
(C) Procedures for referring any eligible 
10
individual who seeks or needs treatment in a 
11
hospital emergency department to a health care 
12
provider who is qualified (as determined by the 
13
State) to provide genetic and genomic testing. 
14
(D) An explanation of how genetic and 
15
genomic testing may improve health outcomes 
16
for all populations in the State, including— 
17
(i) individuals with a rare genetic dis-
18
ease, 
including 
a 
metabolic 
disease, 
19
neurologic disorders, or hereditary cancer 
20
testing in the presence of a suspected or 
21
confirmed cancer diagnosis; and 
22
(ii) special populations, including in-
23
fants and children who are critically ill 
24
(non-infectious and non-trauma) patients, 
25
06:43 Nov 17, 2021
H5989
7 
•HR 5989 IH
transplant patients, individuals with car-
1
diac disease, and individuals with, or who 
2
have a family history of, a birth defect or 
3
developmental disability. 
4
(2) PREFERENCES IN CONSIDERING APPLICA-
5
TIONS.—In considering applications submitted under 
6
paragraph (1), the Secretary of Health and Human 
7
Services shall give preference to States that can 
8
demonstrate underutilization of genetic and genomic 
9
sequencing clinical services (with priority given to 
10
States that do not cover whole-genome sequencing or 
11
do not cover the majority of genetic and genomic 
12
clinical services) in pediatric populations under the 
13
State plan under title XIX of the Social Security Act 
14
(or waiver of such plan). 
15
(d) TECHNICAL
ASSISTANCE.—The Secretary of 
16
Health and Human Services shall provide technical assist-
17
ance to assist States in planning and designing the dem-
18
onstration project for purposes of applying for conducting 
19
such project under this section. 
20
(e) REPORTS BY STATES.—Not later than one year 
21
after the date on which a State enters into an agreement 
22
under subsection (a) with the Secretary for conducting a 
23
demonstration project, the State shall submit a report to 
24
the Administrator of the Centers for Medicare & Medicaid 
25
03:02 Nov 18, 2021
H5989
8 
•HR 5989 IH
Services and the Administrator of the Health Resources 
1
and Services Administration on the extent to which genetic 
2
and genomic testing improved outcomes and reduced 
3
health disparities. Such report shall include information 
4
on the number of patients receiving genetic and genomic 
5
testing, the types of services provided, and such other in-
6
formation as the Secretary shall prescribe. 
7
(f) REPORTS BY HEALTH CARE PROVIDERS.—As a 
8
condition for receiving payment for genetic and genomic 
9
testing provided to an eligible individual under a dem-
10
onstration project conducted by a State under this section, 
11
a health care provider shall report to the State, in accord-
12
ance with such requirements as the Secretary shall specify, 
13
on all applicable measures for determining the quality and 
14
efficacy of such services. 
15
(g) DEFINITIONS.—In this section: 
16
(1) ELIGIBLE INDIVIDUAL.—The term ‘‘eligible 
17
individual’’ means, with respect to a State, an indi-
18
vidual who— 
19
(A) is eligible for medical assistance under 
20
the State plan under title XIX of the Social Se-
21
curity Act (or a waiver of such plan); 
22
(B) is under the age of 21 (or, at the op-
23
tion of the State, under the age of 20, 19, or 
24
18 as the State may choose), or in the case of 
25
06:43 Nov 17, 2021
H5989
9 
•HR 5989 IH
an 
individual 
described 
in 
section 
1
1902(a)(10)(A)(i)(IX) of such Act (42 U.S.C. 
2
1396a(a)(10)(A)(i)(IX)), under the age of 26; 
3
(C) has been referred or admitted to an in-
4
tensive care unit, or has been seen by at least 
5
one medical specialist, for a suspected genetic 
6
or undiagnosed disease; or 
7
(D) is suspected by at least one medical 
8
specialist to have a neonatal-onset or pediatric- 
9
onset genetic disease. 
10
(2) GENETIC
AND
GENOMIC
TESTING.—The 
11
term ‘‘genetic and genomic testing’’, with respect to 
12
an eligible individual— 
13
(A) means the determination of a sequence 
14
of deoxyribonucleic acid bases in the genome of 
15
such individual, and, if for the sole benefit of 
16
the individual, a biological parent of such indi-
17
vidual for the purpose of determining whether 
18
one or more potentially disease-causing genetic 
19
variants are present in the genome of such indi-
20
vidual or such biological parent; and 
21
(B) includes— 
22
(i) the sequencing of the whole ge-
23
nome, the whole exome, or a panel of 
24
genes; and 
25
06:43 Nov 17, 2021
H5989
10 
•HR 5989 IH
(ii) any analysis, interpretation, and 
1
data report derived from such sequencing. 
2
SEC. 4. NATIONAL ACADEMY OF MEDICINE STUDY. 
3
(a) IN GENERAL.—Not later than one year after the 
4
date of the enactment of this Act, the Secretary of Health 
5
and Human Services shall enter into an arrangement with 
6
the National Academy of Medicine under which the Acad-
7
emy agrees to study— 
8
(1) how genetic and genomic testing may im-
9
prove preventative care and precision medicine; 
10
(2) disparities in access to precision diagnostics 
11
and associated therapeutics; 
12
(3) how genetic and genomic testing may be 
13
used to reduce health disparities in marginalized 
14
communities; 
15
(4) how the Federal Government may help to 
16
reduce barriers to genetic and genomic testing, in-
17
cluding— 
18
(A) encouraging the expansion of health 
19
insurance coverage of genetic and genomic test-
20
ing, including diagnostic, predictive, and pre-
21
symptomatic testing, and genetic and genomic 
22
testing (as defined in section 2(h)(2)); 
23
06:43 Nov 17, 2021
H5989
11 
•HR 5989 IH
(B) supporting the collection of evidence 
1
for the clinical utility and appropriate use of ge-
2
netic and genomic tests; and 
3
(C) improving access to genetic counselors, 
4
pathologists, and other relevant professions, in-
5
cluding strengthening related workforce edu-
6
cation and training efforts; 
7
(5)(A) the extent to which coverage provisions 
8
in the Medicare and Medicaid programs under titles 
9
XVIII and XIX of the Social Security Act (42 
10
U.S.C. 1395 et seq., 1396 et seq.) may restrain the 
11
use of genetic and genomic testing that may improve 
12
clinical outcomes for beneficiaries; 
13
(B) the extent to which coverage provided pur-
14
suant to section 2 increased the use of genetic and 
15
genomic testing and improved clinical outcomes for 
16
beneficiaries; and 
17
(C) how the Centers for Medicare & Medicaid 
18
Services may make coverage determinations that 
19
better suit a precision medicine approach to treat-
20
ment; and 
21
(6) how genetic and genomic testing may im-
22
prove health outcomes for all pediatric populations 
23
in the United States, including— 
24
06:43 Nov 17, 2021
H5989
12 
•HR 5989 IH
(A) children with a rare disease, including 
1
a metabolic disease, neurologic disorder, or he-
2
reditary cancer testing in the presence of a sus-
3
pected or confirmed cancer diagnosis; and 
4
(B) special populations, including— 
5
(i) critically ill (non-infectious and 
6
non-trauma) patients; 
7
(ii) transplant patients; 
8
(iii) individuals with cardiac disease; 
9
and 
10
(iv) individuals with, or who have a 
11
family history of, a birth defect or develop-
12
mental disability. 
13
(b) REPORT.— 
14
(1) IN GENERAL.—The arrangement under sub-
15
section (a) shall provide for the National Academy 
16
of Medicine to submit, not later than 2 years after 
17
the date of enactment of this Act, a report on the 
18
results of the study under subsection (a) to— 
19
(A) the Secretary of Health and Human 
20
Services; 
21
(B) the Committee on Ways and Means 
22
and the Committee on Energy and Commerce 
23
of the House of Representatives; and 
24
06:43 Nov 17, 2021
H5989
13 
•HR 5989 IH
(C) the Committee on Finance and the 
1
Committee on Health, Education, Labor, and 
2
Pensions of the Senate. 
3
(2) CONSULTATION.—The arrangement under 
4
subsection (a) shall provide for the National Acad-
5
emy of Medicine, in developing the report required 
6
by paragraph (1), to consult with physicians, other 
7
health professionals, health educators, health profes-
8
sional organizations, relevant companies, patients, 
9
patient organizations, the Health Resources and 
10
Services Administration, the National Cancer Insti-
11
tute, the National Institutes of Health, the Agency 
12
for Healthcare Research and Quality, and the Cen-
13
ters for Medicare & Medicaid Services. 
14
(3) USE
OF
INFORMATION.—The National 
15
Academy of Medicine shall, to the extent possible, in 
16
conducting the study under subsection (a), utilize in-
17
formation included in the reports submitted pursu-
18
ant to subsections (f) and (g) of section 2. 
19
SEC. 5. CENTERS FOR MEDICARE & MEDICAID SERVICES 
20
REPORT ON MEDICAID COVERAGE FOR GE-
21
NETIC AND GENOMIC TESTING. 
22
Not later than one year after the date of the enact-
23
ment of this Act, and annually thereafter for the subse-
24
quent 3 years, the Centers for Medicare & Medicaid Serv-
25
06:43 Nov 17, 2021
H5989
14 
•HR 5989 IH
ices shall submit to the Secretary of Health and Human 
1
Services, the Committees on Ways and Means and on En-
2
ergy and Commerce of the House of Representatives, and 
3
the Committees on Finance and Health, Education, 
4
Labor, and Pensions of the Senate a report on the extent 
5
to which each of the 50 States provide coverage under the 
6
State plan under title XIX of the Social Security Act (or 
7
waiver of such plan) of genetic and genomic testing (as 
8
defined in section 2(f)(2)) (including whole exome, whole 
9
genome, gene panels, single gene tests, Chromosomal 
10
microarray analysis, Fluorescence in situ hybridization, 
11
and other genetic and genomic tests), including informa-
12
tion on— 
13
(1) how often genetic and genomic diagnostic 
14
testing services are covered and reimbursed; 
15
(2) the frequency of denials for coverage and 
16
the rationale for denying coverage; 
17
(3) an analysis of which genetic and genomic 
18
diagnostic tests are being approved or denied; 
19
(4) how often test genetic counseling is covered 
20
pre- and post-genetic and genomic diagnostic test-
21
ing; 
22
(5) the turn-around time for prior authorization 
23
requests; and 
24
06:43 Nov 17, 2021
H5989
15 
•HR 5989 IH
(6) any barriers to coverage of genetic and 
1
genomic testing services identified. 
2
Æ 
06:43 Nov 17, 2021
H5989
